ClinicalTrials.gg
CompletedNCT01515423Updated May 2, 2016Results posted

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

A Phase 3 interventional study of PP3M 175 mg eq. and PP3M 263 mg eq. in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 177 sites in 26 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-05-02.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,429
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
2nd of 115
1,429 · median 178
Started
2012
with 4 others
Phase 3
41 of 115
none open now
Registered
69th of 115
by date
Lead sponsor
12 of 115
Janssen Research & Development, LLC

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 41 in phase 3, and was the 69th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who have been stabilized on PP1M.

Read the detailed description

This is a randomized (the study drug is assigned by chance), double blind (neither physician nor patient knows the treatment that the patient receives), parallel group (each group of patients will be treated at the same time), multicenter non-inferiority (the effect of the new treatment is not worse than that of the comparison treatment) study. A new formulation of paliperidone palmitate with a 3-month injection interval (PP3M) is being tested for use as maintenance treatment for subjects with schizophrenia who have been first stabilized on paliperidone palmitate with a 1-month injection interval (PP1M). The study consists of 3 phases: a screening/washout/tolerability phase (up to 21 days); a 17-week open-label (all people know the identity of the intervention) stabilization phase (referred to as the Open-label Phase) and a 48-week fixed dose, randomized, double-blind controlled phase (referred to as the Double-blind Phase). After completion of the Screening Phase, all patients will receive PP1M in the Open-label Phase. During this time, flexible dosing will occur at Weeks 5 and 9. At Week 13 patients are to receive the dose of PP1M that was administered at Week 9. Patients who are clinically stable at the end of the Open-label Phase will enter the Double-blind Phase and will be randomly assigned in a 1:1 ratio to receive fixed doses of PP3M or PP1M.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • R092670
  • Paliperidone Palmitate
  • Paliperidone palmitate 1 month formulation (PP1M)
  • Paliperidone palmitate 3 month formulation (PP3M)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with schizophrenia for more than 1 year and whose symptoms are worsening in the opinion of the investigator
  • A total score in the Positive and Negative Syndrome Scale (PANSS) between 70 and 120
  • Signed
  • Women must not be pregnant, breastfeeding, and if capable of pregnancy must practice an effective method of
  • Men must agree to use a double-barrier method of birth control
  • Be medically stable on the basis of clinical laboratory tests, physical examination, medical history, vital signs, and (ECG)

Exclusion criteria

Exclusion Criteria:

  • A diagnosis other than schizophrenia, e.g., dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, primary substance-induced psychotic disorder, dementia-related psychosis
  • Relevant history or current presence of any significant or unstable medical condition(s) determined to be by the Investigator (ie, obesity, diabetes, heart disease etc)
  • A diagnosis of substance dependence within 6 months before screening
  • History of neuroleptic malignant syndrome (NMS) or tardive dyskinesia
  • Clozapine use in the last 2 months when used for treatment-resistant or treatment- illness
  • Clinically significant findings in biochemistry, hematology, or urinalysis results
  • Any other disease or condition that, in the opinion of the investigator, would make participation not in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,429 participants (actual)

Study arms

  • Experimental
    Paliperidone palmitate 3-month (PP3M)

    A formulation of paliperidone palmitate with a 3-month injection interval

    Drug: PP3M 175 mg eq. · Drug: PP3M 263 mg eq. · Drug: PP3M 350 mg eq. · Drug: PP3M 525 mg eq. · Drug: Placebo (20% Intralipid)

  • Active comparator
    Paliperidone palmitate 1-month (PP1M)

    A formulation of paliperidone palmitate with a 1-month injection interval

    Drug: PP1M 50 mg eq. · Drug: PP1M 75 mg eq. · Drug: PP1M 100 mg eq. · Drug: PP1M 150 mg eq.

Interventions

  • Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.

  • DrugPlacebo (20% Intralipid)

    Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.

  • DrugPP1M 50 mg eq.

    Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.

  • DrugPP1M 75 mg eq.

    Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.

  • DrugPP1M 100 mg eq.

    Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.

  • DrugPP1M 150 mg eq.

    Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Without Relapse at Week 48 During the Double-Blind Phase

    Relapse defined as: Psychiatric hospitalization;participant had an increase of 25 percent in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was greater than (\>) 40; had a 10 point increase in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was less than or equal to (\<=) 40; deliberate self-injury or exhibited violent behavior resulting in suicide, clinically significant injury;suicidal or homicidal ideation and aggressive behavior;For PANSS items-had a score of greater than or equal to (\>=) 5 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was \<=3 at randomization; had a score of \>=6 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was 4 at randomization.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Change From Double-Blind (DB) Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 48

    The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).

    Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint

  2. Change From DB Baseline in Clinical Global Impression Severity (CGI-S) Scale Score at Week 48

    The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint

  3. Change From DB Baseline in Personal and Social Performance (PSP) Total Score at Week 48

    The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100. Participants with a score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

    Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint

  4. Percentage of Participants Who Met the Criteria for Symptomatic Remission Based on Andreasen Criteria

    Symptomatic remission criterion was defined as having a simultaneous score of mild or less on all selected PANSS items (P1, P2, P3, N1, N4, N6, G5, and G9). Symptomatic remission was defined for the last 6 months of the Double-blind Phase as meeting the remission criterion during the 6 months prior to the End of study visit during the Double-blind Phase, with one excursion allowed.

    Time frame: Weeks 41 to 65

  5. Change From Baseline in Positive and Negative Syndrome Subscales Score at Week 48

    The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).

    Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint

  6. Change From Baseline in Marder Factor Subscale Score at Week 48

    5 PANSS Marder factor scores (positive symptoms \[range:8 to 56\], negative symptoms \[range: 7 to 49\], disorganized thoughts \[range: 7 to 49\], uncontrolled hostility/excitement \[range: 4 to 28\], and anxiety/depression \[range: 4 to 28\]) were examined to gain insight into the symptoms affected by treatment with the study drug. Negative change from baseline in subscales score for positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression indicates improvement in various symptoms of schizophrenia.

    Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint

07

Results

Posted May 2, 2016

Participant flow

Open Label Phase
Participant flow — Open Label Phase
MilestoneOpen-Label: Paliperidone Palmitate (PP1M) 1-month FormulationDouble-Blind: Paliperidone Palmitate(PP3M) 3-month FormulationDouble-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation
Started142900
Completed101600
Not completed41300
Withdrew: Adverse event5700
Withdrew: Death200
Withdrew: Lack of efficacy11700
Withdrew: Lost to follow-up2100
Withdrew: Withdrawal by subject11800
Withdrew: Excluded from db phase7000
Withdrew: Other2800
DOUBLE BLIND
Participant flow — DOUBLE BLIND
MilestoneOpen-Label: Paliperidone Palmitate (PP1M) 1-month FormulationDouble-Blind: Paliperidone Palmitate(PP3M) 3-month FormulationDouble-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation
Started0504512
Completed0422420
Not completed08292
Withdrew: Adverse event01513
Withdrew: Death012
Withdrew: Lost to follow-up0712
Withdrew: Pregnancy020
Withdrew: Withdrawal by subject05053
Withdrew: Other0612
Withdrew: Blind broken by investigator010

Outcome measures

PrimaryPercentage of Participants Without Relapse at Week 48 During the Double-Blind Phase

Relapse defined as: Psychiatric hospitalization;participant had an increase of 25 percent in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was greater than (\>) 40; had a 10 point increase in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was less than or equal to (\<=) 40; deliberate self-injury or exhibited violent behavior resulting in suicide, clinically significant injury;suicidal or homicidal ideation and aggressive behavior;For PANSS items-had a score of greater than or equal to (\>=) 5 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was \<=3 at randomization; had a score of \>=6 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was 4 at randomization.

Time frame:
Up to 48 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Relapse at Week 48 During the Double-Blind Phase
Percentage of ParticipantsDouble Blind: Paliperidone Palmitate 3 Month FormulationDouble Blind: Paliperidone Palmitate 1 Month Formulation
Percentage of Participants Without Relapse at Week 48 During the Double-Blind Phase91.590.0
SecondaryChange From Double-Blind (DB) Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 48

The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).

Time frame:
DB Baseline (Week 17) and 48 week or DB Endpoint
Reported as:
Mean · Units on a scale
Change From Double-Blind (DB) Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 48
Units on a scaleDouble Blind: Paliperidone Palmitate 3 Month FormulationDouble Blind: Paliperidone Palmitate 1 Month Formulation
Baseline57.4 ± 8.5658.1 ± 8.88
Change from Baseline at DB End point-3.5 ± 12.50-4.3 ± 11.78
SecondaryChange From DB Baseline in Clinical Global Impression Severity (CGI-S) Scale Score at Week 48

The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
DB Baseline (Week 17) and 48 week or DB Endpoint
Reported as:
Mean · Units on a scale
Change From DB Baseline in Clinical Global Impression Severity (CGI-S) Scale Score at Week 48
Units on a scaleDouble Blind: Paliperidone Palmitate 3 Month FormulationDouble Blind: Paliperidone Palmitate 1 Month Formulation
Baseline2.9 ± 0.572.9 ± 0.66
Change from Baseline at DB End point-0.1 ± 0.84-0.1 ± 0.75
SecondaryChange From DB Baseline in Personal and Social Performance (PSP) Total Score at Week 48

The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100. Participants with a score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

Time frame:
DB Baseline (Week 17) and 48 week or DB Endpoint
Reported as:
Mean · Units on a scale
Change From DB Baseline in Personal and Social Performance (PSP) Total Score at Week 48
Units on a scaleDouble Blind: Paliperidone Palmitate 3 Month FormulationDouble Blind: Paliperidone Palmitate 1 Month Formulation
Baseline65.5 ± 10.4065.0 ± 11.06
Change from Baseline at DB End point1.3 ± 10.221.9 ± 9.21
SecondaryPercentage of Participants Who Met the Criteria for Symptomatic Remission Based on Andreasen Criteria

Symptomatic remission criterion was defined as having a simultaneous score of mild or less on all selected PANSS items (P1, P2, P3, N1, N4, N6, G5, and G9). Symptomatic remission was defined for the last 6 months of the Double-blind Phase as meeting the remission criterion during the 6 months prior to the End of study visit during the Double-blind Phase, with one excursion allowed.

Time frame:
Weeks 41 to 65
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Met the Criteria for Symptomatic Remission Based on Andreasen Criteria
Percentage of ParticipantsDouble Blind: Paliperidone Palmitate 3 Month FormulationDouble Blind: Paliperidone Palmitate 1 Month Formulation
Percentage of Participants Who Met the Criteria for Symptomatic Remission Based on Andreasen Criteria58.4 (0.89 to 1.08)59.2 (0.89 to 1.08)
SecondaryChange From Baseline in Positive and Negative Syndrome Subscales Score at Week 48

The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).

Time frame:
DB Baseline (Week 17) and 48 week or DB Endpoint
Reported as:
Mean · Units on a scale
Change From Baseline in Positive and Negative Syndrome Subscales Score at Week 48
Units on a scaleDouble Blind: Paliperidone Palmitate 3 Month FormulationDouble Blind: Paliperidone Palmitate 1 Month Formulation
Positive subscale: Baseline11.9 ± 3.1212.0 ± 3.19
Positive subscale:Change at Endpoint-0.6 ± 4.31-0.9 ± 3.70
Negative subscale: Baseline17.3 ± 4.2717.3 ± 4.11
Negative subscale:Change at Endpoint-1.4 ± 3.63-1.4 ± 3.67
General psychopathology : Baseline28.2 ± 4.5528.8 ± 4.79
General psychopathology : Change at Endpoint-1.4 ± 6.77-2.0 ± 6.57
SecondaryChange From Baseline in Marder Factor Subscale Score at Week 48

5 PANSS Marder factor scores (positive symptoms \[range:8 to 56\], negative symptoms \[range: 7 to 49\], disorganized thoughts \[range: 7 to 49\], uncontrolled hostility/excitement \[range: 4 to 28\], and anxiety/depression \[range: 4 to 28\]) were examined to gain insight into the symptoms affected by treatment with the study drug. Negative change from baseline in subscales score for positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression indicates improvement in various symptoms of schizophrenia.

Time frame:
DB Baseline (Week 17) and 48 week or DB Endpoint
Reported as:
Mean · Units on a scale
Change From Baseline in Marder Factor Subscale Score at Week 48
Units on a scaleDouble Blind: Paliperidone Palmitate 3 Month FormulationDouble Blind: Paliperidone Palmitate 1 Month Formulation
Positive symptoms factor: Baseline15.7 ± 3.6615.8 ± 3.88
Positive symptoms factor:Change at Endpoint-1.1 ± 4.61-1.4 ± 4.16
Negative symptoms factor: Baseline16.2 ± 4.0316.3 ± 3.90
Negative symptoms factor : Change at Endpoint-1.4 ± 3.57-1.3 ± 3.80
Disorganized thoughts factor :Baseline14.2 ± 3.2014.3 ± 3.17
Disorganized thoughts factor:Change at Endpoint-1.2 ± 3.36-1.2 ± 3.24
Uncontrolled hostility Factor:Baseline5.2 ± 1.645.4 ± 1.77
Uncontrolled hostility Factor:Change at Endpoint0.2 ± 2.31-0.2 ± 2.21
Anxiety/depression factor:Baseline6.1 ± 2.026.3 ± 2.12
Anxiety/depression factor:Change at Endpoint-0.0 ± 2.69-0.2 ± 2.43

Adverse events

Collected over From signing of informed consent form up to Follow-Up Visit (4 or 12 Weeks after study drug administration). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation—101/1,429 (7.1%)457/1,429 (32%)
Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation—26/504 (5.2%)212/504 (42.1%)
Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation—37/512 (7.2%)208/512 (40.6%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventOpen-Label: Paliperidone Palmitate (PP1M) 1-month FormulationDouble-Blind: Paliperidone Palmitate(PP3M) 3-month FormulationDouble-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation
SchizophreniaPsychiatric disorders31/142912/50411/512
Psychotic DisorderPsychiatric disorders14/14291/5042/512
Suicide AttemptPsychiatric disorders3/14290/5044/512
Hallucination, AuditoryPsychiatric disorders6/14291/5040/512
Suicidal IdeationPsychiatric disorders6/14290/5040/512
Psychiatric SymptomPsychiatric disorders4/14292/5042/512
AnxietyPsychiatric disorders4/14290/5042/512
DelusionPsychiatric disorders4/14291/5042/512
Schizophrenia, Paranoid TypePsychiatric disorders0/14290/5042/512
AkathisiaNervous system disorders4/14290/5040/512
Most frequent other events
Most frequent other events
EventOpen-Label: Paliperidone Palmitate (PP1M) 1-month FormulationDouble-Blind: Paliperidone Palmitate(PP3M) 3-month FormulationDouble-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation
Weight IncreasedInvestigations64/1429105/504109/512
Injection Site PainGeneral disorders127/142912/50414/512
NasopharyngitisInfections and infestations66/142936/50433/512
InsomniaPsychiatric disorders94/142916/50424/512
AnxietyPsychiatric disorders79/142927/50422/512
AkathisiaNervous system disorders78/142920/50414/512
HeadacheNervous system disorders46/142918/50426/512
Injection Site IndurationGeneral disorders40/142914/5046/512
Weight DecreasedInvestigations10/142914/50414/512
HypertensionVascular disorders11/142912/5047/512

Baseline characteristics

The safety analysis set included all participants who were randomly assigned to treatment during the Double-blind Phase and received at least 1 dose study drug.

Age, Continuous
Age, Continuous(years)Double-Blind: Paliperidone Palmitate(PP3M) 3-month FormulationDouble-Blind: Paliperidone Palmitate(PP1M) 1-month FormulationTotal
Mean39.0 ± 11.8938.3 ± 12.2438.6 ± 12.06
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind: Paliperidone Palmitate(PP3M) 3-month FormulationDouble-Blind: Paliperidone Palmitate(PP1M) 1-month FormulationTotal
Female246231477
Male258281539
Region of Enrollment
Region of Enrollment(participants)Double-Blind: Paliperidone Palmitate(PP3M) 3-month FormulationDouble-Blind: Paliperidone Palmitate(PP1M) 1-month FormulationTotal
China104106210
Russian Federation7575150
Japan5256108
United States414889
Ukraine352964
Czech Republic312960
Hungary211940
Poland172037
Argentina141630
Bulgaria121628
Brazil131225
Spain111425
Slovakia121022
Portugal111021
Mexico7916
Taiwan7714
Romania7613
Germany8412
South Korea7512
Belgium7411
Greece5611
Canada369
Australia325
France123
Austria011
08

Study locations

177 sites
  • Little Rock, Arkansas, United States
  • Glendale, California, United States
  • Long Beach, California, United States
  • Oakland, California, United States
  • Oceanside, California, United States
  • Orange, California, United States
  • San Diego, California, United States
  • New Britain, Connecticut, United States
  • Bradenton, Florida, United States
  • Kissimmee, Florida, United States
  • Tampa, Florida, United States
  • Wichita, Kansas, United States
  • East Lansing, Michigan, United States
  • St. Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Jamaica, New York, United States
  • Durham, North Carolina, United States
  • Canton, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • Bothell, Washington, United States
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Córdoba, Argentina
  • Rosario, Argentina
  • Elizabeth Vale, Australia
  • Frankston, Australia
  • Innsbruck, Austria
  • Assebroek, Belgium
  • Bertrix, Belgium
  • Brussel - Jette, Belgium
  • Dave, Belgium
  • Heusden, Belgium
  • Marchienne-Au-Pont, Belgium
  • Sint-Denijs-Westrem, Belgium
  • Rio De Janeiro, Brazil
  • Bourgas N/A, Bulgaria
  • Kazanlak, Bulgaria
  • Radnevo, Bulgaria
  • Sofia, Bulgaria
  • Calgary, Alberta, Canada
  • Halifax, Ontario, Canada
  • Montreal, Quebec, Canada
  • Burlington, Canada
  • Baoding, China
  • Beijing, China
  • Changsha, China
  • Guangdong, China
  • Guangzhou, China
  • Hangzhou, China
  • Kunming, China
  • Shanghai, China
  • Tianjin, China
  • Wuhan, China
  • Xi'An, China
  • Brno, Czech Republic
  • Horovice, Czech Republic
  • Liberec, Czech Republic
  • Praha 10, Czech Republic
  • Praha 9, Czech Republic
  • Prerov, Czech Republic
  • Clermont Ferrand, France
  • Dole, France
  • Montpellier, France
  • Toulon, France
  • Bochum, Germany
  • Gelsenkirchen, Germany
  • Hamburg, Germany
  • Heidelberg, Germany
  • München, Germany
  • Arta, Greece
  • Athens, Greece
  • Katerini, Greece
  • Balassagyarmat N/A, Hungary
  • Budapest, Hungary
  • Gyõr, Hungary
  • Kalocsa, Hungary
  • Sopron, Hungary
  • Aizuwakamatsu, Japan
  • Fujioka, Japan
  • Fujisawa, Japan
  • Hadano, Japan
  • Himeji, Japan
  • Hitachi, Japan
  • Ichikawa, Japan
  • Kanuma, Japan
  • Kanzaki, Japan
  • Kashihara, Japan
  • Kashiwara, Japan
  • Kasuya, Japan
  • Kawasaki, Japan
  • Kitagunma, Japan
  • Kochi, Japan
  • Kodaira, Japan
  • Kumagaya, Japan
  • Kumamoto, Japan
  • Kure, Japan

Showing the first 100 of 177 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M. Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study. Neuropsychiatr Dis Treat. 2020 Mar 6;16:681-690. doi: 10.2147/NDT.S226296. eCollection 2020. PubMed 32184607 ↗
  • Savitz AJ, Xu H, Gopal S, Nuamah I, Mathews M, Soares B. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. Braz J Psychiatry. 2019 Nov-Dec;41(6):499-510. doi: 10.1590/1516-4446-2018-0153. PubMed 30994855 ↗
  • Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. Neuropsychiatr Dis Treat. 2019 Mar 22;15:731-737. doi: 10.2147/NDT.S194264. eCollection 2019. PubMed 30962688 ↗
  • Mathews M, Pei H, Savitz A, Nuamah I, Hough D, Alphs L, Gopal S. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. Clin Drug Investig. 2018 Aug;38(8):695-702. doi: 10.1007/s40261-018-0647-z. PubMed 29882073 ↗
  • Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. Clin Pharmacokinet. 2017 Apr;56(4):421-433. doi: 10.1007/s40262-016-0459-3. PubMed 27743205 ↗
  • Samtani MN, Nandy P, Ravenstijn P, Remmerie B, Vermeulen A, Russu A, D'hoore P, Baum EZ, Savitz A, Gopal S, Hough D. Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy. Br J Clin Pharmacol. 2016 Nov;82(5):1364-1370. doi: 10.1111/bcp.13050. Epub 2016 Jul 24. PubMed 27333588 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2012
First posted
Jan 24, 2012
Start
May 2012
Primary completionActual
Feb 2015
CompletionActual
Mar 2015
Results first posted
May 2, 2016
Last update
May 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01515423
Responsible party
Sponsor
First posted
Jan 24, 2012
Start date
May 2012
Primary completion
Feb 2015
Completion
Mar 2015
Results posted
May 2, 2016
Last update
May 2, 2016

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion